Skip NavigationSkip to Content

Cholecystokinin-B Receptor-Targeted Nanoparticle for Imaging and Detection of Precancerous Lesions in the Pancreas

  1. Author:
    Smith, Jill P.
    Cao, Hong
    Edmondson,Elijah
    Dasa,Siva Sai Krishna
    Stern,Steve
  2. Author Address

    Georgetown Univ, Dept Med, Washington, DC 20007 USA.Frederick Natl Lab Canc Res, Mol Pathol Lab, Frederick, MD 21701 USA.NCI, Nanotechnol Characterizat Lab, Canc Res Technol Program, Frederick Natl Lab Canc Res, Frederick, MD 21701 USA.
    1. Year: 2021
    2. Date: Dec
  1. Journal: BIOMOLECULES
  2. MDPI,
    1. 11
    2. 12
  3. Type of Article: Article
  4. Article Number: 1766
  5. ISSN: 2218-273X
  1. Abstract:

    Survival from pancreatic cancer remains extremely poor, in part because this malignancy is not diagnosed in the early stages, and precancerous pancreatic intraepithelial neoplasia (PanIN) lesions are not seen on routine radiographic imaging. Since the cholecystokinin-B receptor (CCK-BR) becomes over-expressed in PanIN lesions, it may serve as a target for early detection. We developed a biodegradable fluorescent polyplex nanoparticle (NP) that selectively targets the CCK-BR. The NP was complexed to a fluorescent oligonucleotide with Alexa Fluor 647 for far-red imaging and to an oligonucleotide conjugated to Alexa Fluor 488 for localization by immunohistochemistry. Fluorescence was detected over the pancreas of five- to ten-month-old LSL-Kras(G12D/+); P48-Cre (KC) mice only after the injection of the receptor target-specific NP and not after injection of untargeted NP. Ex vivo tissue imaging and selective immunohistochemistry confirmed particle localization only to PanIN lesions in the pancreas and not in other organs, supporting the tissue specificity. A human pancreas tissue microarray demonstrated immunoreactivity for the CCK-BR only in the PanIN lesions and not in normal pancreas tissue. The long-term goal would be to develop this imaging tool for screening human subjects at high risk for pancreatic cancer to enable early cancer detection.

    See More

External Sources

  1. DOI: 10.3390/biom11121766
  2. PMID: 34944412
  3. PMCID: PMC8698999
  4. WOS: 000736230800001

Library Notes

  1. Fiscal Year: FY2021-2022
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel